CELU
Celularity Inc
NASDAQ: CELU · HEALTHCARE · BIOTECHNOLOGY
$0.93
-2.68% today
Updated 2026-04-30
Market cap
$32.01M
P/E ratio
—
P/S ratio
0.79x
EPS (TTM)
$-3.33
Dividend yield
—
52W range
$1 – $4
Volume
0.2M
Celularity Inc (CELU) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | $17.55M | $21.15M | $14.28M | $21.34M | $17.98M | $22.77M | $54.22M |
| Revenue growth (YoY) | — | +20.5% | -32.5% | +49.4% | -15.7% | +26.7% | +138.1% |
| Cost of revenue | $6.55M | $6.32M | $4.93M | $9.65M | $19.66M | $16.02M | $14.99M |
| Gross profit | $11.00M | $14.82M | $9.35M | $11.68M | $-1.69M | $6.75M | $39.23M |
| Gross margin | 62.7% | 70.1% | 65.5% | 54.8% | -9.4% | 29.7% | 72.4% |
| R&D | $29.06M | $46.05M | $52.71M | $88.35M | $78.36M | $30.46M | $17.39M |
| SG&A | — | $40.63M | $30.57M | $71.09M | $65.86M | $50.58M | $58.62M |
| Operating income | $-1098.00 | $-264.13M | $-151.93M | $-109.06M | $-25.60M | $-76.48M | $-38.36M |
| Operating margin | -0.0% | -1249.0% | -1064.0% | -511.2% | -142.4% | -335.9% | -70.7% |
| EBITDA | $-1098.00 | $-70.98M | $-202.41M | $-88.11M | $-138.83M | — | $-43.71M |
| EBITDA margin | -0.0% | -335.6% | -1417.6% | -413.0% | -772.4% | 0.0% | -80.6% |
| EBIT | $-4.79M | $-77.16M | $-210.58M | $-96.93M | $-148.27M | — | $-51.63M |
| Interest expense | $0.00 | $3.75M | $2.35M | $3.17M | $3.17M | $3.02M | $6.26M |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-1098.00 | $-211.88M | $-208.23M | $-100.12M | $14.19M | $-196.29M | $-57.89M |
| Net income growth (YoY) | — | -19296894.5% | +1.7% | +51.9% | +114.2% | -1483.1% | +70.5% |
| Profit margin | -0.0% | -1001.9% | -1458.4% | -469.3% | 79.0% | -862.0% | -106.8% |